Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00493038 |
This is a clinical study organized to collect clinical data to better define the activity of some antimicrobials already marketed in Italy and in the rest of the world for the treatment of acute bacterial rhinosinusitis
Condition | Intervention | Phase |
---|---|---|
Sinusitis Bacterial Infections |
Drug: Avelox (Moxifloxacin, BAY12-8039) Drug: Amoxicilline / clavulanate |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety Study |
Official Title: | Prospective, Multicenter, Randomized, Double Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg OD for 7 Days Versus a Standard Antibiotic Therapy for 10 Days in the Treatment of Acute Bacterial Rhino Sinusitis |
Enrollment: | 594 |
Study Start Date: | February 2006 |
Study Completion Date: | January 2008 |
Primary Completion Date: | January 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental |
Drug: Avelox (Moxifloxacin, BAY12-8039)
Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days
|
Arm 2: Active Comparator |
Drug: Amoxicilline / clavulanate
Patient will be administered daily Amoxicilline/clavulanate 1000 mg tablets every 8 hours for 10 days
|
Number of arms: 2
(Group A: Moxifloxacin 400 mg tablets OD for 7 days and amoxicilline/clavulanate 1000 mg matching placebo tablets TID for 10 days; Group B: Amoxicilline/clavulanate 1000 mg tablets TID for 10 days and Moxifloxacin 400 mg matching placebo tablets OD for 7 days.)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Italy | |
Siena, Italy, 53100 | |
Roma, Italy, 00151 | |
Pisa, Italy, 56126 | |
Roma, Italy, 00184 | |
Foggia, Italy, 71100 | |
Bergamo, Italy, 24128 | |
Lecce, Italy, 73100 | |
Roma, Italy, 00135 | |
Lecco, Italy, 23900 | |
Matera, Italy, 75100 | |
Catania, Italy, 95126 | |
Treviso, Italy, 31100 | |
Caserta, Italy, 81100 | |
Pavia, Italy, 27100 | |
Bari, Italy, 70123 | |
Novara, Italy, 28100 | |
Bolzano, Italy, 39100 | |
Firenze, Italy, 50126 | |
Milano, Italy, 20122 | |
Catania, Italy, 95123 | |
Perugia, Italy, 06126 | |
Torino, Italy, 10141 | |
Bologna, Italy, 40138 | |
Torino, Italy, 10126 | |
Milano, Italy, 20142 | |
Benevento, Italy, 82100 | |
Udine, Italy, 33100 | |
Italy, Ascoli Piceno | |
San Benedetto del Tronto, Ascoli Piceno, Italy, 63039 | |
Italy, Brescia | |
Esine, Brescia, Italy, 25040 | |
Italy, Catanzaro | |
Lamezia Terme, Catanzaro, Italy, 88046 | |
Italy, Forlì | |
Cesena, Forlì, Italy, 47023 | |
Italy, Genova | |
Sestri Ponente, Genova, Italy, 16154 | |
Italy, Milano | |
Monza, Milano, Italy, 20052 | |
Italy, Ragusa | |
Comiso, Ragusa, Italy, 97013 |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer S.p.A. ( Medical Affairs Therapeutic Area Head ) |
Study ID Numbers: | 11881, EudraCT 2005-002779-34 |
Study First Received: | June 26, 2007 |
Last Updated: | October 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00493038 |
Health Authority: | Italy: Ministry of Health |
Treatment of acute bacterial rhinosinusitis |
Bacterial Infections Amoxicillin Otorhinolaryngologic Diseases Respiratory Tract Infections Respiratory Tract Diseases |
Moxifloxacin Clavulanic Acid Clavulanic Acids Sinusitis Amoxicillin-Potassium Clavulanate Combination |
Anti-Infective Agents Anti-Bacterial Agents Molecular Mechanisms of Pharmacological Action Paranasal Sinus Diseases Therapeutic Uses |
Enzyme Inhibitors Infection Pharmacologic Actions Nose Diseases |